Seres Therapeutics, Inc. (MCRB)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Eric D. Shaff M.B.A. | President, CEO & Director | 1.11M | -- | 1976 |
| Mr. Thomas J. DesRosier Esq., J.D. | Chief Legal Officer, Executive VP & Secretary | 707.14k | -- | 1955 |
| Ms. Marella Thorell CPA | Executive VP & CFO | -- | -- | 1967 |
| Dr. Matthew R. Henn Ph.D. | Executive VP & Chief Scientific Officer | 643.83k | -- | 1975 |
| Dr. Teresa L. Young Ph.D., R.Ph. | Executive VP and Chief Commercial & Strategy Officer | 606.33k | -- | 1967 |
| Mr. Chris McChalicher | Senior VP of Manufacturing, Quality, and Process Development | -- | -- | -- |
| Dr. Dennis M. Walling M.D. | Senior VP of Clinical Development & Head of Clinical Research | -- | -- | -- |
| Ms. Ann Kurowski | Senior Vice President of Regulatory Affairs | -- | -- | -- |
| Ms. Kelly Brady | Senior Vice President of Clinical Development | -- | -- | -- |
| Ms. Caroline Hensley | Assistant General Counsel | -- | -- | -- |
Seres Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 103
Description
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
August 11, 2025 at 12:30 PM UTC - August 15, 2025 at 12:30 PM UTC
Seres Therapeutics, Inc. Earnings Date